Sartorius Stedim Biotech Launches Sartoguard NF Prefilter Series

· Innovative nanofleece technology provides high flow rates and total throughput performance in combination with excellent clarification capabilities
· New series concludes the launch of SSB´s Sartoguard range of prefilters

Goettingen, Germany and  Aubagne, France,  December 5, 2012 / B3C newswire / – Sartorius Stedim Biotech (SSB), a leading international pharma supplier, has launched the Sartoguard NF prefilter series, completing its range of Sartoguard prefilters. These new prefilters feature a unique combination of high performance polyethersulfone (PES) membranes and highly innovative nanofleece technology. This is the first time that PES nanofleece material is being used for liquid prefiltration applications in biopharmaceutical manufacturing. The newly developed nanofleece technology provides an ultrafine fleece structure based on a small nanofiber diameter of 120-150 nm compared with the fiber diameter of conventional fleece materials of >500 nm. The resulting fleece structure offers enhanced clarification capabilities, even for extremely fine contaminants, along with a high-dirt holding capacity, fast flow rates and high total throughput performance.

The new Sartoguard NF prefilter series combines high flow rates and total throughput performance

Sartoguard NF prefilters are the ideal choice for downstream protection of more expensive sterilizing-grade and Mycoplasma-retentive filters in challenging prefiltration applications for biopharmaceutical manufacturing. In combination with their high total throughput performance, Sartoguard NF prefilters offer significant cost-saving potential due to their ultrafine retention performance, which ensures removal even of extremely small particulate-based contaminants. All active filter materials – membranes and nanofleece – of the new prefilter series are made of polyethersulfone, thus ensuring a minimum extractable footprint. This enables users to easily implement Sartoguard NF into existing filtration processes utilizing final filters already based on PES.

Sartoguard NF filter elements are available in all common filter formats offered by Sartorius Stedim Biotech, such as SartoScale devices for small-scale filterability trials, as well as MidiCaps, MaxiCaps and standard filter cartridges for medium- and commercial-scale manufacturing. Sartoguard NF MidiCaps and MaxiCaps are the first fully gamma irradiatable prefilter series and can be easily integrated into single-use process equipment.

Sartoguard NF filters conclude the launch of the Sartoguard prefilter family, which includes the Sartoguard PES and Sartoguard GF prefilter series that have been successfully introduced to the market earlier. The launch of the Sartoguard prefilter family is an important contribution by Sartorius Stedim Biotech in reducing overall filtration costs in biopharmaceutical manufacturing and in helping biomanufacturers cope with the increasing cost pressure while maintaining and improving their high quality standards.

About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.” Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 2,850 people, and in 2011 earned sales revenue of 477.,3 million euros.

Contacts for Sartorius Stedim Biotech

Dominic Grone
Group Corporate Communications
+49 (0)551 308.3324
dominic.grone@sartorius.com

Karin Kleist
Group Corporate Communications
+49 (0)551 308.3615
karin.kleist@sartorius.com